

Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy Men

AMMAR QOUBAITARY,* CRISTINA MERIGGIOLA,† CHIU MING NG,* LESLIE LUMBRERAS,* SILVIA CERPOLINI,† G. PELUSI,† PETER D. CHRISTENSEN,* LAURA HULL,* RONALD S. SWERDLOFF,* AND CHRISTINA WANG*

From the *Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, California; and the †Department of Obstetrics and Gynecology, University of Bologna, Bologna, Italy.

ABSTRACT: Long-acting injectable testosterone undecanoate (TU) is a promising androgen for male hormonal contraception. As a prerequisite for a planned multicenter male contraceptive efficacy study, we studied the pharmacokinetics of 2 doses of TU alone or in combination with norethisterone enanthate (NETE) in a prospective 2-center study, randomized for TU dose in each center. Twenty healthy male volunteers in each center were administered intramuscular injections of 750 or 1000 mg TU alone or in combination with 200 mg of NETE IM every 8 weeks for 3 injections. There were no significant differences in maximum concentration and area under the curve (AUC) for serum total and free testosterone (T) between the TU 750 and 1000 mg groups, irrespective of whether TU was administered with 200 mg of NETE. TU 1000 mg IM alone or with

NETE at 8-weekly intervals resulted in linear increases in average concentration and AUC of serum total and free T with each injection. Accumulation ratios of serum total and free T levels (calculated as 8 weeks post- to preinjection levels) for each period showed significant increases in the TU+ NETE groups. Serum gonadotropins levels and sperm concentration were more consistently suppressed in the TU 1000 mg + NETE group. We conclude that despite some accumulation of T, TU 1000 mg + NETE 200 mg administered every 8 weeks may be preferable for the future contraceptive efficacy study because of more complete suppression of gonadotropins and spermatogenesis.

Key words: Azoospermia, oligozoospermia, male contraception. *J Androl* 2006;27:853–867

Reliable, reversible, safe, and preferably long-acting methods of hormonal male contraception might allow men to participate in family planning with higher compliance. At present, all potential male hormonal contraceptives require an androgen for suppression of gonadotropins and spermatogenesis while maintaining androgenicity of healthy adult men. Testosterone enanthate (TE) administered as an intramuscular (IM) injection once every 2 to 3 weeks is the most common injectable androgen used for the treatment of hypogonadal men (Snyder and Lawrence, 1980; Sokol et al, 1982). Testosterone undecanoate (TU), formulated as a longer lasting injectable preparation was first studied in Chinese hypogonadal men. In these studies, 500- or

1000-mg intramuscular (IM) TU injections in tea seed oil resulted in serum testosterone (T) levels within the adult male range for about 4 to 6 weeks (Zhang et al, 1998). Subsequent studies in Europe (using a preparation in castor oil that was different from the formulation developed in China) with single and repeated 1000-mg IM injections of TU maintained normal adult male physiological serum T levels in hypogonadal men for 12 weeks (Behre et al, 1999; Nieschlag et al, 1999; Von Eckardstein and Nieschlag, 2002; Schubert et al, 2004). Recent studies showed that TU injections improved sexual function and muscle and bone mass in hypogonadal men (Jockenhovel, 2004; Schubert et al, 2004; Qoubaitary et al, 2005). These studies provided evidence that TU could maintain serum T within or above the adult range with much less frequent injections than were required for TE; the need for less frequent injections suggested a more patient convenient regimen that could improve adherence to treatment for hypogonadism and male contraception. TU was first utilized in male contraception clinical trials in Chinese men when administration of TU 500-mg and 1000-mg IM injections monthly led to azoospermia in 11/12 volunteers in the 500-mg and all volunteers in the 1000-mg group (Zhang et al, 1999). A large multicenter efficacy study

Supported by the Contraceptive Research and Development Program (CIG-03-94, CIG-04-99), the GCRC at Harbor-UCLA Medical Center (MO1 RR00425), and the Endocrinology and Metabolism Training grant (T32 DK007571).

Correspondence to: Dr Christina Wang, General Clinical Research Center, Box 16, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509 (e-mail: Wang@labiomed.org.edu).

Received for publication April 13, 2006; accepted for publication July 11, 2006.

Presented in part at ENDO 2005, San Diego, June 2005.

DOI: 10.2164/jandrol.106.000281

involving 308 men showed that azoospermia was achieved in 97% of Chinese men when TU was administered with an initial loading dose of 1000 mg followed by 500 mg at monthly intervals (Gu et al, 2003).

The efficacy of TU in suppressing spermatogenesis was also demonstrated in 14 white men who were administered TU 1000 mg every 6 weeks, where 86% of the men became severely oligozoospermic (Kamischke et al, 2000). It is generally recognized from prior studies that Asian men respond to exogenous T injections with more efficacious suppression of spermatogenesis than non-Asian men (World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1990; World Health Organization Task Force on Methods for the Regulation of Male Fertility, 1996). The relatively lower sperm suppression of androgens alone in non-Asian men led to the concept of combined preparations, whereby a second gonadotropin suppressor (ie, progestin or GnRH analogue) is added to the androgen to optimize sperm suppression (Meriggiola and Bremner, 1997; Anderson and Baird, 2002; Amory and Bremner, 2003; Nieschlag et al, 2003; Wang and Swerdloff, 2004). Norethisterone enanthate (NETE) is a progestin that has weak androgenic and estrogenic activity and has been used as a 2-monthly injectable female contraceptive in many countries (Kessuru-Koos et al, 1973; Sang et al, 1981; Fotherby et al, 1984).

When NETE 200 mg was combined with TU 1000 mg injections every 6 weeks, suppression of spermatogenesis was enhanced compared to TU alone (Kamischke et al, 2001; Kamischke et al, 2002). In a more recent study, this high efficacy of spermatogenic suppression was maintained even when the frequency of injections was extended to once every 8 weeks (Meriggiola et al, 2005). Based on these promising data on relatively few men, a proposed large international multicenter study to examine the contraceptive efficacy in many couples utilizing a combination of 8-weekly intervals of TU and NETE injections has been planned. The dose of TU has not been determined; 1000 mg was proposed, but data from a lower dose of TU, such as 750 mg, had not been tested. To ensure that TU administered IM every 8 weeks will provide adequate T levels without any significant accumulation of the steroid while suppression of spermatogenesis is optimized, a detailed pharmacokinetics study of TU in healthy men was warranted. The purpose of this study was to characterize pharmacokinetics of TU administered at 750 or 1000 mg IM every 8 weeks that would be optimal for male contraceptive clinical studies, either alone or in combination with NETE administered at the same intervals in healthy male volunteers.

Materials and Methods

Subjects

Forty (20 in each center) healthy men aged between 18 and 50 years were enrolled in the study (Table 1). In Los Angeles, 7 of the volunteers were white, 6 Hispanic, 4 African American, 1 was Asian, and 2 were Pacific islanders, whereas in Bologna all subjects were white. All men were in good general health as confirmed by medical history and physical examination. They had normal baseline hematology, blood chemistry, urinalysis, and fasting lipid profile, a prostate-specific antigen level of less than 4 ng/mL, and a urine flow rate of over 15 mL/s. All volunteers had normal reproductive hormones and 2 normal semen analyses. As the end points of the study included serum hormone concentrations and semen quality, the study did not require the participants to have proven fertility. Men with history of chronic diseases or positive hepatitis serology or drug screen were excluded. Digital rectal examination was performed at the beginning and end of study, and any abnormality was noted. Testis volume was assessed by the Prader orchidometer (Test-Size Orchidometer; Accurate Surgical & Scientific Instruments Corp, Westbury, NY) (Prader, 1966) at the Los Angeles site by 2 moderately experienced physicians and at Bologna by 1 experienced physician. The physicians did not have an opportunity to compare their assessment on the same subject between the centers.

Study Design

This was a 2-center prospective study consisting of a 2-week baseline period, 24-week treatment period, and 8-week recovery period which was extended until each subject had sperm counts above 20 million/mL. We have recently shown that if sperm concentrations returned to 20 million/mL, it is most likely that the sperm concentration will return to the baseline concentration (Liu et al, 2006). The 2 centers were the Division of Endocrinology, Department of Medicine, Harbor-UCLA Medical Center, Los Angeles, California and the Department of Obstetrics and Gynecology, University of Bologna, S. Orsola Hospital, Italy. Subjects studied in Los Angeles were randomized to receive 3 injections of 750 mg or 1000 mg TU at 8-weekly intervals (TU alone group). Because of drug regulatory limitations, it was not possible to use NETE in the United States, and the study of TU plus NETE was performed in Italy. Subsequently, in Bologna the same protocol was utilized to study the pharmacokinetics of TU at doses of 750 and 1000 mg together with 200 mg NETE IM every 8 weeks for 3 injections (TU + NETE group). Subjects in Bologna were also randomized to receive either TU 750 or 1000 mg injections. Blood samples were drawn between 7 and 10 AM for serum total and free T; 5- α dihydrotestosterone (DHT) and estradiol (E_2) were drawn at day 0 and then at weekly intervals. Serum FSH, LH, and sex hormone binding globulin (SHBG) were measured at monthly intervals. Serum hormones were also drawn at week 32 during recovery. Semen analyses were obtained every 4 weeks during the treatment period and every 8 weeks during recovery. Physical examination and

Table 1. Baseline clinical and biochemical parameters of subjects

| | Los Angeles | | Bologna | | P-value |
|----------------------------------|-------------|-----------|---------|-----------|---------|
| | Mean | Range | Mean | Range | |
| Age (years) | 31.7 | 24–47 | 33.5 | 20–46 | .42 |
| Weight (kg) | 91.5 | 55–125 | 76.4 | 60–96 | .004 |
| Height (cm) | 177 | 167–184 | 178 | 166–192 | .66 |
| BMI (kg/m ²) | 29.1 | 19.8–39.5 | 24.1 | 20.2–31.1 | .001 |
| Serum T (nmol/L) | 16.1 | 5.4–31.4 | 19.0 | 12.3–30.3 | .13 |
| Free T (nmol/L) | 0.26 | 0.10–0.43 | 0.34 | 0.18–0.66 | .02 |
| SHBG (nmol/L) | 27.9 | 13.5–67.9 | 30.3 | 12.5–62.6 | .54 |
| DHT (nmol/L) | 3.62 | 1.26–7.62 | 4.29 | 1.27–14.2 | .33 |
| E ₂ (pmol/L) | 159 | 128–257 | 156 | 104–262 | .75 |
| FSH (IU/L) | 2.68 | 1.21–6.86 | 2.91 | 1.12–4.88 | .56 |
| LH (IU/L) | 2.86 | 1.31–5.63 | 4.07 | 1.52–7.89 | .01 |
| Testis volume (mL) | 52.3 | 40–70 | 39.9 | 36–44 | <.0001 |
| Sperm concentration (million/mL) | 80.7 | 16–182 | 40.4 | 21–102 | .0002 |

safety laboratory tests were done before, at week 12 and 24 of treatment, and at week 32 during recovery.

Medications

TU was supplied by Schering AG (Berlin, Germany) and through the Contraceptive Research and Development program (CONRAD) program (Arlington, Va). Each ampoule contained 1000 mg of TU dissolved in 4 mL of castor oil. This preparation used in the present study is the same as that reported in the European studies (Behre et al, 1999; Nieschlag et al, 1999; Kamischke et al, 2000; Kamischke et al, 2001) and different from the formulation used in China. The preparation was shaken vigorously before injection. For the 1000-mg dose 4 mL was administered, and for the 750-mg dose 3 mL was given. The injections were given as deep IM injections into the gluteal regions slowly to avoid pain associated with the injection. The same batch of TU was used throughout the study. TU is absorbed into the circulation and rapidly metabolized into the active unesterified T and the undecanoate side-chain. The undecanoate moiety undergoes β -oxidation, with 2 carbon pieces entering the citric acid cycle. The residual 3 carbon piece (Propionyl-CoA) is converted to propionylcarnitine and excreted in the urine. The undecanoate moiety has no biological action (information from Schering AG). NETE was supplied by Schering to Dr Meriggiola. For the 200-mg dose, 1 mL was administered. The injections were given as deep IM injections into the gluteal regions separate from the TU injections. Experienced nurses at both centers gave all the injections under the supervision of the investigators.

Methods

Serum samples from Bologna were stored at -20°C and shipped frozen in batches to Los Angeles. All samples from a subject were measured in the same assay to reduce interassay variation. All hormone and SHBG assays used validated methods established at Harbor-UCLA Endocrine Research laboratory. The methods used to measure these hormones as well as SHBG had been previously described (Swerdlow et al, 2000; Wang et al, 2004) except serum total and free T, which

had been modified and briefly described below. Serum T levels were measured by a specific RIA-using kit from Diagnostic Product Corporation (Los Angeles, Calif). The lower limit of quantitation (LLOQ) of serum T measured for this assay was 0.43 nmol/L. All results below this value were reported as 0.43 nmol/L. The mean accuracy (recovery) of the T assay, determined by spiking steroid free serum with varying amounts of T (0.9 nmol/L to 56 nmol/L), was 104% (range 95% to 114%). The intra- and interassay coefficients of variation for the T assay were 4.0% and 5.8%, respectively, at the normal adult male range (established by obtaining sera from over 120 healthy men of mixed ethnicity who had normal physical examination and semen analyses and normal serum gonadotropin levels), which in our laboratory were 9.4 to 30.9 nmol/L (271 to 892 ng/dL). Serum free T was measured by the equilibrium dialysis method using purified radioactive labeled T and dialyzed overnight in dialysis cells at 37°C . The labeled T that was in the dialysate expressed as a percent of the total amount of labeled added to the serum was used to calculate the percent free T. The free T concentration was then derived by serum total T concentration \times percent free. The intra- and interassay precisions (CV) of percent free T were 6.3% and 10.6%. The adult male reference range for free T values in our laboratory was 0.127 to 0.576 nmol/L (3.66 to 16.62 ng/dL).

Semen analyses were performed using methods described by the WHO Manual for the Examination of Human Semen and Sperm Cervical Mucus Interaction (World Health Organization, 1999). Harbor-UCLA Andrology participated in the external proficiency testing provided by the College of American Pathologists, and the Bologna center participated in Valutazione Esterna di Qualità, Gruppo Controllo Qualità Analitico Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi. All safety laboratory tests, including serum PSA, were measured at each center's clinical biochemistry laboratories. At Harbor-UCLA Medical Center, the PSA was quantitated using 2-site chemiluminescent Beckman Access Hybritech total PSA assay (inter-assay CV 5.2% and 4.2% at low and high PSA levels; Beckman Coulter, Fullerton, Calif), and in Bologna, immunofluorescent assays (inter-assay CV 2.1% for both high and low range; KRYP-

TOR; CIS-Bio International, Oris Group, Gif-sur-Yvette, France).

Statistical Analyses

For each of the three 8-week injection periods and for each of the 4 subject groups, derived pharmacokinetics measures for T and free T were calculated. These measures include C_{avg} = mean concentration, C_{max} = maximum concentration, AUC = area under the curve using the trapezoidal method, accumulation ratio = ratio of the 8-week postinjection concentration to preinjection concentration, and response ratio = ratio of the 1-week postinjection concentration to preinjection concentration.

T, free T, SHBG, DHT, E2, sperm concentration, and baseline FSH and LH were log-transformed prior to analysis and are summarized as geometric means. All other measures were summarized as arithmetic means, except posttreatment LH and FSH, for which medians were used for summarization, since many values were at the lower limit of quantification of the assay. (Note that in the figures, for simplicity mean and SEM are shown, except for serum LH and FSH levels, where medians and box plots are used.) Baseline subject characteristics were compared between Los Angeles and Bologna subjects with *t* tests. Correlation between testis volume and other parameters were by Pearson correlation analyses. Comparison of pharmacokinetic measures over the three 8-week injection periods and between subject groups were performed with repeated measures analysis of variance (ANOVA), using period as a repeated measure and group as a classification factor and using linear contrasts to assess trends over subsequent injection periods. Baseline BMI was added to these models to adjust group differences in pharmacokinetic measures for BMI, which tended to be greater in the Los Angeles subjects. Posttreatment FSH and LH were compared between subject groups with nonparametric Wilcoxon tests. Percentages of subjects attaining azoospermia or oligozoospermia were compared between groups with Fisher's exact tests. Trends over time in body weight, cholesterol (total, LDL, and HDL), serum chemistry, liver function tests, hematocrit, hemoglobin, PSA, and testis volume were assessed with repeated measures ANOVA for separate subject groups.

Results

Subjects

All subjects completed the study. Summary baseline demographic, clinical, and hormonal characteristics of the subjects at the time of randomization are shown in Table 1. All parameters were within the normal range. Mean body weight and BMI were significantly higher in the subjects in Los Angeles. Mean serum free T and LH levels were significantly higher in the subjects in Bologna, and mean sperm concentration and testis volume were significantly higher in the subjects in Los Angeles; all other baseline hormone levels and semen parameters were similar between the 2 groups. It is well

recognized that measurement of testis volume using orchidometers has large inter- and intraobserver variances and may be dependent on the experience of the observers (Behre et al, 1989). The difference in the mean testis volume, though significant, might be due to a systematic measuring difference between the 2 centers. On further analyses the participants in this study showed pretreatment positive associations of sperm concentration (and also total sperm count per ejaculate) with testis volume (Pearson correlation $> .48$; $P < .002$) and with abstinence time (Pearson correlation $> .29$; $P < .06$), and that larger men had larger testes (BMI-testis volume Pearson correlation = $.39$; $P = .01$). However, these subject characteristics were not at all associated with treatment effect. For example, mean testis volume, BMI, and abstinence time were almost identical for subjects who were severely oligozoospermic compared to those who were not at 24 weeks (45.7 vs 46.5 mL, 26.6 vs 26.7 kg/m², and 2.5 vs 2.5 days, respectively; *t* tests $P > .65$).

Serum Testosterone

Figure 1 (top panel) shows serum T concentrations after injections of TU 750 mg or 1000 mg IM alone or with NETE 200 mg IM every 8 weeks. The maximum (C_{max}) serum T concentrations and area under the serum T curve (AUC) were similar between the 750 and 1000 mg dose, irrespective of whether TU was administered alone or with NETE (Table 2). The average concentrations of serum T (C_{avg}) were higher in the TU 1000-mg group compared to the 750-mg group when administered alone after the second ($P = .03$) and third ($P = .01$) injections (Table 2). Mean C_{avg} and AUC of serum total T increased steadily over the 3 periods for the 1000-mg dose TU groups, irrespective of whether NETE was coadministered ($P \leq .02$). These parameters did not significantly increase over injection periods for the 750-mg dose groups, although a similar trend was present. Note from Figure 1 that the mean serum T levels 8 weeks after the first TU injection were lower than pre-first injection (baseline levels), the mean pre- and 8 weeks post-second injection serum T levels were approximately equal, and the mean serum T concentrations 8 weeks after the third injection was greater than pre-third injection levels for both 750-mg dose groups and in the 1000-mg TU + NETE group. Thus, mean accumulation ratios (defined as the ratio of serum T level at 8 weeks postinjection to preinjection level) significantly increased with subsequent injections for all groups except the TU 1000-mg alone group.

Serum Free T

The serum free T levels mimicked the serum total T levels (Figure 1, bottom panel). There were no signifi-




Figure 1. Serum total (top panel) and free T (bottom panel) levels in the subjects. Subjects in Los Angeles were administered TU 1000 or 750 mg every 8 weeks for 3 injections; subjects in Bologna received NETE 200 mg at the same time as the TU injections.

cant differences in mean C_{avg} , C_{max} , and AUC for free T between the 2 dose groups with only TU, or between the 2 TU + NETE groups. The mean immediate response ratios significantly increased with each injection in the TU + NETE groups ($P \leq .03$), with similar, but nonsignificant, trends for the TU only groups. The C_{avg} ($P < .01$), AUC ($P < .02$), and accumulation ratio ($P < .01$) increased significantly with repeated injections for both TU + NETE groups, with similar, but nonsignificant, trends for the TU only groups. TU alone and TU + NETE groups did not differ significantly, with the following exceptions.

The mean C_{avg} for free T was significantly greater for TU + NETE compared with TU alone after each 1000-mg TU injection ($P \leq .03$) and after second ($P < .04$) and third ($P < .01$) 750-mg TU injections, and mean AUC for TU + NETE was significantly greater than TU only groups after the second and third injections ($P < .02$). These differences (except C_{avg} after the second injection) in serum free T parameters between the TU alone vs TU + NETE were markedly attenuated to become nonsignificant after adjustment for BMI, which tended to be greater in the TU groups in Los Angeles.

Table 2. Mean pharmacokinetic parameters for serum T after TU injection with or without NETE injections co-administered at weeks 0, 8, and 16

| | TU 1000 mg | TU 750 mg | TU 1000 mg + NETE 200 mg | TU 750 mg + NETE 200 mg |
|----------------------------------|------------|-----------|--------------------------|-------------------------|
| <i>C</i> _{avg} (nmol/L) | | | | |
| 0–8 weeks | 17.9 | 14.8 | 16.7 | 15.9 |
| 8–16 weeks | 19.6* | 14.5* | 18.0 | 17.0 |
| 16–24 weeks | 21.1* | 15.8* | 20.0 | 18.4 |
| <i>P</i> -value for trend | .01 | .20 | .02 | .06 |
| <i>C</i> _{max} (nmol/L) | | | | |
| 0–8 weeks | 32.4 | 29.8 | 27.0 | 25.0 |
| 8–16 weeks | 34.5 | 32.2 | 38.1 | 29.5 |
| 16–24 weeks | 37.2 | 31.5 | 28.6 | 28.7 |
| <i>P</i> -value for trend | .21 | .66 | .52 | .26 |
| AUC (nmol·wk/l) | | | | |
| 0–8 weeks | 154.4 | 140.4 | 136.7 | 138.4 |
| 8–16 weeks | 175.5 | 149.2 | 154.3 | 152.6 |
| 16–24 weeks | 185.2 | 155.7 | 163.7 | 160.3 |
| <i>P</i> -value for trend | .02 | .16 | .01 | .08 |
| Accumulation ratio | | | | |
| Wk 8 / Wk 0 | 0.92 | 0.82 | 0.72 | 0.72 |
| Wk 16 / Wk 8 | 0.92 | 0.90 | 1.00 | 1.06 |
| Wk 24 / Wk 16 | 1.04 | 1.11 | 1.27 | 1.23 |
| <i>P</i> -value for trend | .33 | .03 | <.0001 | .003 |
| Response ratio | | | | |
| Wk 1/Wk 0 | 1.85 | 1.88 | 1.26 | 1.25 |
| Wk 9/Wk 8 | 2.26 | 2.33 | 2.11 | 2.08 |
| Wk 17/Wk 16 | 2.65 | 2.57 | 1.82 | 1.66 |
| <i>P</i> -value for trend | .03 | .14 | .06 | .02 |

* *P* < .05 for TU 1000 mg vs TU 750 mg.

Serum DHT and E₂

Serum DHT (Figure 2, top panel) and E₂ (Figure 2, bottom panel) levels paralleled those shown by serum total T concentrations. There were no significant differences in mean serum DHT (*C*_{avg}) and DHT AUC between the 2 doses of TU when TU was administered with NETE (*P* > .37), but were greater in the 1000-mg TU group compared to the 750-mg TU group without NETE after the second (*P* < .05) and third (*P* < .005) injections. There were no significant differences in mean serum E₂ *C*_{avg} and E₂ AUC between the 2 doses of TU when TU was administered without NETE (*P* > .28), but were greater with the 1000-mg TU group compared to the 750-mg TU group with concurrent NETE administration after the third injection (*P* < .05), but not with the first 2 injections (*P* > .15).

Serum SHBG

Figure 3 shows that there were no significant differences in the time course of serum SHBG levels between the 2 doses of TU whether or not NETE was given concurrently (*P* > .24). Serum SHBG was not significantly suppressed with TU alone (*P* = .20). As

anticipated from our knowledge of androgenic progestin effects on SHBG levels, serum SHBG levels were significantly (*P* < .0001) suppressed to an average of 58% and 61% of baseline at 4 weeks after each injection of 1000 and 750 mg of TU + NETE respectively.

Serum Gonadotropins

The changes in serum gonadotropins (median with 25 and 75 percentiles shown in the box plots) are shown in Figure 4a and b. At 4 weeks after the first injection, median serum LH concentrations were suppressed below 0.6 IU/L and reached 0.1 IU/L after the second and the third injections of either 750 and 1000 mg of TU. Median serum LH levels rebounded after the first and second injections in both TU 750 mg and 1000 mg alone groups, though the rebound became less with each injection. Addition of NETE induced suppression of LH to median levels of 0.1 IU/L 4 weeks after each injection in both TU dose groups. Median serum LH remained suppressed to this very low level after the second injection in the TU 1000 mg + NETE group but not in the TU 750 mg + NETE group. There were no significant differences in serum LH levels between TU 1000-mg and 750-mg dose groups used alone or with NETE, except at week 16 for the NETE groups, when




Figure 2. Serum DHT (top panel) and E₂ (bottom panel) levels in the subjects administered TU alone or TU with NETE.

the 1000-mg dose had a significantly ($P = .02$) lower median LH than the 750-mg dose. Serum FSH followed a pattern similar to serum LH (Figure 4b). Median serum FSH was suppressed at 4 weeks and rebounded at 6 to 8 weeks after each injection. Only in the TU 1000 mg + NETE group were median serum FSH levels persistently suppressed to 0.1 IU/L from week 20 onwards. Median serum FSH levels were lower ($P \leq .06$) in the TU 1000 mg + NETE when compared to TU 750 mg + NETE group at all time points. Serum FSH were similar ($P \geq .12$) at all times for TU 1000-mg and TU 750-mg groups.

Sperm Concentration

Sperm concentrations fell significantly in all subjects. All subjects recovered to over 20 million/mL (Figure 5). Median 24-week sperm concentrations were zero in both 1000-mg TU groups (though 3 subjects in the TU 1000 mg only group had sperm concentration over 20 million/mL), and 1.41 and 0.10 million/mL for the 750-mg TU and 750-mg TU + NETE groups, respectively ($P = .46$). The median time of recovery to 20 million/mL was week 40 (24 weeks post-third dose) in the TU alone groups and also week 40 in the TU + NETE groups. Figure 6 shows the percentages of




Figure 3. Serum SHBG levels in the subjects administered TU alone or TU with NETE.

subjects with sperm concentration suppressed to 0 and <1 million/mL. At some time during treatment, 3/10 and 5/10 subjects in the TU 750-mg group and 6/10 and 8/10 in the TU 1000-mg group achieved azoospermia or <1 million/mL, respectively, whereas 5/10 and 7/10 in the TU 750 mg + NETE and 7/10 and 10/10 subjects in the TU 1000 mg + NETE group achieved azoospermia and <1 million/mL respectively. Because the study is not powered to examine differences in suppression of spermatogenesis, the differences between the groups were not statistically significant.

Safety Parameters and Adverse Events

There were no significant changes serum chemistry and liver functions tests in all 4 groups of subjects. Serum total and LDL cholesterol did not change in all treatment groups. Whereas in both NETE groups, but in neither TU only groups, mean serum HDL cholesterol decreased during treatment and partially rebounded during recovery for the TU 1000 mg + NETE group ($P = .0002$) and for the TU 750 mg + NETE group ($P = .01$) (Table 3). In the TU 750 mg NETE group, serum calcium decreased during treatment: pretreatment, 12 week, and 24 week respectively ($P = .004$). The changes in calcium levels were very small and not clinically significant. TU 750 mg administered every 8 weeks alone or with NETE did not result in significant increases in hematocrit or hemoglobin. In contrast, significant increases in hematocrit and hemoglobin were observed in both the TU 1000 mg alone group ($P = .01$) and TU 1000 mg + NETE group ($P = .006$) (Table 3).

Hemoglobin followed the same trend, with mean increases of 0.7 ($P = .005$) and 1.0 g/dL ($P = .01$) in the TU 1000 μ g alone or with NETE groups respectively.



There was one serious adverse event of penicillin hypersensitivity, which was considered to be unrelated to drug exposure. Three subjects complained of transient pain and swelling at the injection sites. The pain was mild in severity and resolved spontaneously with no treatment. Other side effects of androgen treatment included oily skin that was mild and required no treatment. Overall, approximately twice as many subjects gained weight as lost weight (26 gained, 2 stable, 12 lost), with a significant mean increase, although subjects were very heterogeneous in their weight changes (mean \pm SD = 1.7 ± 3.7 kg; $P < .05$). There were no significant differences according to dose or center/use of progestin or their interaction (ANOVA $P > .15$). Specifically, mean (range) weight changes were 1.7 (−7.7 to 6.9), 1.4 (−4.0 to 7.0), 0.49 (−2.8 to 5.1), and 3.4 (−4.0 to 11.0) kg for the 750 mg TU, 750 mg TU + NETE, 1000 mg TU, and 1000 mg TU + NETE-E groups, respectively. None of volunteers developed gynecomastia, prostate enlargement (estimated by digital rectal examination), significant changes in urine flow, or increases in serum PSA levels. Changes in sexual function or mood were not reported. Mean testis volume decreased from baseline to 12 weeks to 24 weeks in both the TU without NETE group (52.3 ± 1.7 , 48.5 ± 2.2 , and 47.6 ± 2.4 mL, respectively; $P = .01$) and the TU + NETE group (39.9 ± 0.41 , 38.3 ± 0.50 , and 37.4 ± 0.70 mL, respectively; $P = .0005$).

Discussion

In this study, we determined pharmacokinetics of TU injections administered at 750 and 1000 mg IM either alone or in combination with NETE every 8 weeks for 3 injections in healthy male volunteers. The study was initiated in Los Angeles, and because NETE is not available in the United States, the Bologna center joined the study for the groups being administered the combination of TU and NETE using an identical protocol to that in Los Angeles. This study was done to determine the optimal dose of TU to be used in combination with 8-weekly injections of NETE in a planned late phase 2 contraceptive efficacy trial involving a relatively large number of couples. The goal was to achieve optimal suppression of gonadotropins and spermatogenesis with the lowest possible amount of T to be delivered to the body to maintain eugonadal state while enhancing the effect of NETE on gonadotropin and spermatogenic suppression. The duration of 8 weeks was chosen because pharmacokinetics of NETE in prior studies in women (Sang et al, 1981; Fotherby et al, 1984) suggested that a longer interval might result in inadequate level of NET for suppression of gonadotropins. Moreover, a previous preliminary report showed that NETE 200 mg administered with TU 1000 mg at 8-weekly intervals induced a profound sperm suppression that was not maintained when the injection interval was extended to 12 weeks (Meriggiola et al, 2005). Though serum T levels had been studied in eugonadal subjects (Zhang et al, 1999; Kamischke et al, 2000) after administration of TU 1000-mg and 500-mg injections every 4 to 6 weeks, the dose of 750 mg has never been administered before to normal or hypogonadal men, and detailed pharmacokinetics were not available for TU 1000 mg administered IM every 8 weeks in healthy men.

We showed that there were no significant differences in C_{max} and AUC between the 2 doses of TU injections, irrespective of whether the TU was given concurrently with NETE. The C_{avg} for serum T and DHT was significantly higher in the TU 1000-mg group when administered alone after the second and third injections, but this was not observed when NETE was added. For both doses there was an accumulation of serum T after each injection, which was more pronounced when NETE was given in addition to the TU injections. Linear increases in C_{avg} , AUC, and immediate response ratios suggested there was accumulation of T with both doses, but more with the 1000-mg dose. The accumulation of serum T was relatively small, as the serum T level at week 24 (8 weeks after the third injection) was not significantly different from baseline levels in all

treatment groups. Subtle differences in the pharmacokinetic measures might not have been detected in this study because of the small group size of 10 men. In our experimental paradigm, no loading dose of TU was administered. This resulted in lower serum T levels at 8 weeks after the first injection compared to preinjection baseline. The predose serum T levels rose after each injection to reach baseline levels by the third injection. Because of this characteristic of TU, a loading dose may prevent the serum T levels falling to below baseline before the next scheduled injection. The recommended dose of TU for androgen replacement in hypogonadal men by the manufacturer of TU (package insert for Nebido injections) is to give a second 1000 mg of TU 6 weeks after the initial TU 1000-mg injection, followed by maintenance injections at 12 weekly intervals (Jockenhovel, 2004; Goubaitary et al, 2005). Furthermore, the reported contraceptive efficacy trial in China also employed a loading dose of 1000 mg followed by 500 mg TU every 4 weeks (Gu et al, 2003). Our study did not include a loading dose of TU, with the intention of keeping the proposed hormonal contraception regimen as simple as possible for the proposed large multicenter study. Serum free T followed the same pattern as serum T. Apparent higher serum free T levels were detected in the group where TU was administered with NETE. One reason for this difference could be due to the suppressed SHBG levels occurring after NETE administration, resulting in more free T in the groups administered the progestin in addition to the androgen. In this study serum total T, however, was not different between the groups receiving TU alone or TU + NETE, where the greater level of suppression of SHBG should result in a lower serum total T level in the TU + NETE group. Subjects were not randomized to whether NETE was administered, and thus TU + NETE vs TU only group differences may be attributable to subject differences as well as to the effect of NETE, and this confounding can be only partially examined with statistical adjustment. When we examined the subjects in Los Angeles (TU alone) and Bologna (TU + NETE), we noted that while their mean height was not different, the body weight and BMI were significantly greater in the men in Los Angeles, and their baseline free T levels were lower. The baseline free T levels were significantly higher in the Italian men. The Italian subjects had lower body weight and BMI, but they were healthy and not undernourished, whereas the subjects in Los Angeles were generally heavier. It is well known that higher body weight and BMI are inversely related to total serum T and free T (Glass et al, 1977; Vermeulen et al, 1996; Gapstur et al, 2002; Jensen et al, 2004). Such differences in serum total T levels have recently been reported in a prior study utilizing testosterone and levonorgestrel






Figure 5. Sperm concentrations in subjects administered TU alone or TU with NETE.

implants between leaner men in Nanjing, China and heavier non-Asian men in Los Angeles (Wang et al, 2006). When statistical adjustment for subject differences in BMI was made, the significance of the differences was attenuated, and BMI largely explained the differences in free T C_{avg} levels between the Los Angeles and Bologna subjects after all 3 injections of the 750-mg TU dose ($P > .79$), but not the 1000-mg dose ($.03 \leq P \leq .08$). The remaining differences could be related to the more significant suppression of SHBG in those receiving TU + NETE, an androgenic progestin.

At baseline serum LH was higher in the subjects in Bologna despite a higher serum free T level. The reason for this difference between the subjects is not clear and is probably not clinically significant. The subjects in Bologna had lower mean testis volume and mean sperm concentration than the subjects in Los Angeles. The difference in testis volume may be due to variances in measurement by different observers. However analyses showed significant positive correlations between sperm count, total sperm count, BMI, and testis volume, indicating that the observed differences are influenced by body size and spermatogenic rate. Such associations had been previously reported in many ethnic groups (Handelsman et al, 1984; Aribarg et al, 1986; Ku et al, 2002). It has also been reported both in Europe and in

the United States that geographical differences in sperm concentration do occur (Jorgensen et al, 2001; Jorgensen et al, 2002; Swan et al, 2003). Despite the fact that no apparent differences in pharmacokinetics were found between the 2 doses of TU, the suppression of both gonadotropins to very low levels was significantly better achieved by the TU 1000 mg both with and without NETE. Only in the group receiving TU 1000 mg + NETE were the gonadotropins persistently suppressed after the second injection to levels that were close to the limit of detection. As a corollary to the more persistent gonadotropin suppression, TU 1000 mg + NETE 200 mg administered every 8 weeks led to the consistent suppression of sperm concentration to $<1 \times 10^6/mL$ in all subjects at 24 weeks of treatment. This dose, however, as discussed above, caused some accumulation of serum total and free T levels, though serum T levels at the end of treatment were similar to those at baseline. The higher dose of TU 1000 mg every 8 weeks also resulted in a linear trend for increases in hematocrit and hemoglobin by a small amount, which remained within the physiological range of adult healthy men. There was mild weight gain which was not significantly different among the treatment groups. The lower dose of TU 750 mg + NETE 200 mg maintained T levels within the physiologic range; however, serum FSH and LH levels

←

Figure 4. Serum LH (a) and FSH (b) levels in the subjects administered TU alone or TU with NETE. The line within the box represents the median, the box the 25th and 50th percentiles, and the whiskers 10th and 90th percentiles.




Figure 6. Percentage subjects achieving azoospermia or severe oligozoospermia (<1 million/mL) after administration of TU alone or TU with NETE.

rebounded 6 to 8 weeks after each injection. Fewer subjects achieved suppression of sperm concentration <1 million/mL at 24 weeks of treatment. The differences in sperm suppression may become less apparent with more prolonged use of TU + NETE; however, during the 6 months of treatment in this study the suppression of spermatogenesis with the lower dose would generally be considered inadequate for male contraception. One may also suggest that increasing the dose of NETE may blunt this gonadotropin rebound. Previous studies testing the dose of NETE 400 mg every 8 weeks did not offer an advantage in spermatogenic suppression over NETE 200 mg (Kamischke et al,

2002). We noted that the TU and NETE injections were well tolerated by the subjects during the study period. TU alone did not cause any changes in serum cholesterol levels, but addition of NETE resulted in statistically significant suppression of HDL-cholesterol, as reported for other androgenic progestins such as levonorgestrel (Anawalt et al, 1999; Wu et al, 1999; Kamischke et al, 2001). Only 3 subjects expressed some mild and transient pain and swelling at the injection site after a 4-mL injection. There were no clinical significant adverse effects related to the T during the study.

We conclude that the detailed pharmacokinetics analyses of TU injections, given at 750 mg and

Table 3. Safety parameters after TU and NETE injections

| Measurement (units) | Visits | Los Angeles (TU Only) | | Bologna (TU+ NETE) | |
|----------------------------------|--------|-----------------------|------------|--------------------|------------|
| | Week | 750 mg | 1000 mg | 750 mg | 1000 mg |
| Serum calcium (mmol/L) | Screen | 2.35±0.02 | 2.38±0.02 | 2.34±0.03 | 2.33±0.04 |
| | 12 | 2.35±0.03 | 2.34±0.03 | 2.26±0.02 | 2.30±0.03 |
| | 24 | 2.33±0.02 | 2.37±0.02 | 2.35±0.03 | 2.32±0.04 |
| | 32 | 2.33±0.04 | 2.33±0.03 | 2.34±0.03 | 2.32±0.02 |
| Serum total cholesterol (mmol/L) | Screen | 5.20±0.33 | 4.83±0.19 | 4.50±0.38 | 4.65±0.32 |
| | 12 | 5.36±0.40 | 5.21±0.26 | 4.49±0.34 | 4.13±0.32 |
| | 24 | 5.23±0.32 | 5.04±0.25 | 4.62±0.34 | 4.42±0.29 |
| | 32 | 5.42±0.34 | 5.15±0.19 | 4.59±0.38 | 4.55±0.28 |
| Serum HDL cholesterol (mmol/L) | Screen | 1.13±0.06 | 0.98±0.08 | 1.45±0.11 | 1.35±0.08 |
| | 12 | 1.10±0.06 | 1.03±0.11 | 1.24±0.07 | 1.15±0.06 |
| | 24 | 1.12±0.09 | 1.02±0.12 | 1.38±0.11 | 1.24±0.06 |
| | 32 | 1.13±0.07 | 1.04±0.12 | 1.41±0.11 | 1.40±0.07 |
| Serum LDL cholesterol (mmol/L) | Screen | 3.55±0.29 | 3.23±0.18 | 2.59±0.30 | 2.75±0.31 |
| | 12 | 3.77±0.37 | 3.64±0.29 | 2.89±0.27 | 2.49±0.29 |
| | 24 | 3.58±0.26 | 3.40±0.25 | 2.71±0.23 | 2.61±0.25 |
| | 32 | 3.71±0.30 | 3.39±0.22 | 2.70±0.33 | 2.63±0.29 |
| Hematocrit (L/L) | Screen | 0.44±0.006 | 0.45±0.007 | 0.44±0.009 | 0.43±0.009 |
| | 12 | 0.46±0.010 | 0.46±0.004 | 0.43±0.011 | 0.45±0.017 |
| | 24 | 0.45±0.009 | 0.47±0.005 | 0.45±0.014 | 0.46±0.015 |
| | 32 | 0.44±0.010 | 0.45±0.006 | 0.45±0.012 | 0.44±0.014 |
| Hemoglobin (g/L) | Screen | 150.8±2.3 | 152.4±2.7 | 151.7±2.9 | 143.4±4.6 |
| | 12 | 155.0±3.7 | 155.4±2.1 | 147.5±4.2 | 149.4±6.6 |
| | 24 | 152.6±3.7 | 159.7±2.2 | 154.6±4.8 | 153.0±5.9 |
| | 32 | 149.7±3.8 | 153.0±2.4 | 154.2±4.1 | 149.2±6.1 |
| Serum PSA (ug/L) | Screen | 0.56±0.06 | 0.56±0.10 | 0.69±0.12 | 0.68±0.10 |
| | 12 | 0.93±0.19 | 0.64±0.11 | 0.84±0.13 | 0.92±0.17 |
| | 24 | 0.61±0.08 | 0.58±0.09 | 0.74±0.13 | 1.05±0.32 |
| | 32 | 0.57±0.06 | 0.77±0.24 | 0.72±0.13 | 0.78±0.14 |

1000 mg every 8 weeks for 3 injections, showed no detectable dose response difference in normal volunteers. The higher dose of TU 1000 mg may result in more accumulation of T, though the serum level was not different from baseline after 3 injections. We only examined a course of 3 injections, so accumulation may become more pronounced with a more long-term regimen of injections every 8 weeks resulting in serum T concentrations towards the upper half of the adult male range. The higher dose also resulted in elevated hematocrit, which remained in the physiological range. However, in view of the more consistent suppression of gonadotropins without rebound and consequently greater inhibition of spermatogenesis, we recommend that the phase 2 studies should consider using TU 1000 mg with NETE every 8 weeks to attain optimal efficacy. During the treatment duration, preinjection serum T levels and red cell parameters should be monitored to assess whether changes in these parameters are persistent. The alternatives of administering 750 mg TU every 6 weeks or using a loading dose of TU 1000 mg followed by maintenance with 750 mg were not tested in the study; TU 1000 mg every 10 weeks was not considered because of the known pharmacokinetics of the accompanying NETE, necessitating injections every 8 weeks.

Acknowledgments

We thank the nurses and the core laboratory of the GCRC at Harbor-UCLA for their assistance with the study and Mr Andrew Leung and Ms Sima Baravarian of the Endocrine Research Laboratory for some of the hormone assays. We thank CONRAD for their support of this study and Schering AG for providing the TU and NETE.

References

- Amory JK, Bremner WJ. Regulation of testicular function in men: implications for male hormonal contraceptive development. *J Steroid Biochem Mol Biol.* 2003;85:357–361.
- Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. *J Androl.* 1999;20:407–414.
- Anderson RA, Baird DT. Male contraception. *Endocr Rev.* 2002;23:735–762.
- Aribarg A, Kenkeerati W, Vorapaiboonsak V, Leepipatpaiboon S, Farley TM. Testicular volume, semen profile and serum hormone levels in fertile Thai males. *Int J Androl.* 1986;9:170–180.
- Behre HM, Abshagen K, Oettel M, Hubler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. *Eur J Endocrinol.* 1999;140:414–419.
- Behre HM, Nashan D, Nieschlag E. Objective measurement of testicular volume by ultrasonography: evaluation of the technique

- and comparison with orchidometer estimates. *Int J Androl.* 1989;12:395–403.
- Fotherby K, Hamawi A, Howard G, Bye PG, Elder M. Pharmacokinetics of different doses of norethisterone oenanthate. *Contraception.* 1984;29:325–333.
- Gapstur SM, Gann PH, Kopp P, Colangelo L, Longcope C, Liu K. Serum androgen concentrations in young men: a longitudinal analysis of associations with age, obesity, and race. The CARDIA male hormone study. *Cancer Epidemiol Biomark Prev.* 2002;11:1041–1047.
- Glass AR, Swerdloff RS, Bray GA, Dahms WT, Atkinson RL. Low serum testosterone and sex-hormone-binding-globulin in massively obese men. *J Clin Endocrinol Metab.* 1977;45:1211–1219.
- Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY. A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. *J Clin Endocrinol Metab.* 2003;88:562–568.
- Handelsman DJ, Conway AJ, Boylan LM, Turtle JR. Testicular function in potential sperm donors: normal ranges and the effects of smoking and varicocele. *Int J Androl.* 1984;7:369–382.
- Jensen TK, Andersson AM, Jorgensen N, Andersen AG, Carlsen E, Petersen JH, Skakkebaek NE. Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. *Fertil Steril.* 2004;82:863–870.
- Jockenhovel F. Testosterone therapy—what, when and to whom? *Aging Male.* 2004;7:319–324.
- Jorgensen N, Andersen AG, Eustache F, Irvine DS, Suominen J, Petersen JH, Andersen AN, Auger J, Cawood EH, Horte A, Jensen TK, Jouannet P, Keiding N, Vierula M, Toppari J, Skakkebaek NE. Regional differences in semen quality in Europe. *Hum Reprod.* 2001;16:1012–1019.
- Jorgensen N, Carlsen E, Nermoen I, Punab M, Suominen J, Andersen AG, Andersson AM, Haugen TB, Horte A, Jensen TK, Magnus O, Petersen JH, Vierula M, Toppari J, Skakkebaek NE. East-West gradient in semen quality in the Nordic-Baltic area: a study of men from the general population in Denmark, Norway, Estonia and Finland. *Hum Reprod.* 2002;17:2199–2208.
- Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, Nieschlag E. An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. *J Clin Endocrinol Metab.* 2002;87:530–539.
- Kamischke A, Ploger D, Venherm S, von Eckardstein S, von Eckardstein A, Nieschlag E. Intramuscular testosterone undecanoate with or without oral levonorgestrel: a randomized placebo-controlled feasibility study for male contraception. *Clin Endocrinol (Oxf).* 2000;53:43–52.
- Kamischke A, Venherm S, Ploger D, von Eckardstein S, Nieschlag E. Intramuscular testosterone undecanoate and norethisterone enanthate in a clinical trial for male contraception. *J Clin Endocrinol Metab.* 2001;86:303–309.
- Kessuru-Koos E, Larranaga-Legufa A, Hurtado-Koo H, Scharff HJ. Fertility control with norethindrone enanthate, a long-acting parenteral progestogen. *Acta Eur Fertil.* 1973;4:203–221.
- Ku JH, Kim ME, Jeon YS, Lee NK, Park YH. Factors influencing testicular volume in young men: results of a community-based survey. *BJU Int.* 2002;90:446–450.
- Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. *Lancet.* 2006;367:1412–1420.
- Meriggiola MC, Bremner WJ. Progestin-androgen combination regimens for male contraception. *J Androl.* 1997;18:240–244.
- Meriggiola MC, Costantino A, Saad F, D'Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G. Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. *J Clin Endocrinol Metab.* 2005;90:2005–2014.
- Nieschlag E, Buchter D, von Eckardstein S, Abshagen K, Simoni M, Behre HM. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men. *Clin Endocrinol (Oxf).* 1999;51:757–763.
- Nieschlag E, Zitzmann M, Kamischke A. Use of progestins in male contraception. *Steroids.* 2003;68:965–972.
- Prader A. Testicular size: Assessment and clinical importance. *Triangle.* 1966;7:240–253.
- Qoubaitary A, Swerdloff RS, Wang C. Advances in male hormone substitution therapy. *Expert Opin Pharmacother.* 2005;6:1493–1506.
- Sang GW, Fotherby K, Howard G, Elder M, Bye PG. Pharmacokinetics of norethisterone oenanthate in humans. *Contraception.* 1981;24:15–27.
- Schubert M, Minnemann T, Hubler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhovel F. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. *J Clin Endocrinol Metab.* 2004;89:5429–5434.
- Snyder PJ, Lawrence DA. Treatment of male hypogonadism with testosterone enanthate. *J Clin Endocrinol Metab.* 1980;51:1335–1339.
- Sokol RZ, Palacios A, Campfield LA, Saul C, Swerdloff RS. Comparison of the kinetics of injectable testosterone in eugonadal and hypogonadal men. *Fertil Steril.* 1982;37:425–430.
- Swan SH, Brazil C, Drobnis EZ, Liu F, Kruse RL, Hatch M, Redmon JB, Wang C, Overstreet JW. Geographic differences in semen quality of fertile U.S. males. *Environ Health Perspect.* 2003;111:414–420.
- Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. *J Clin Endocrinol Metab.* 2000;85:4500–4510.
- Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. *J Clin Endocrinol Metab.* 1996;81:1821–1826.
- Von Eckardstein S, Nieschlag E. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. *J Androl.* 2002;23:419–425.
- Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 2004;89:2085–2098.
- Wang C, Swerdloff RS. Male hormonal contraception. *Am J Obstet Gynecol.* 2004;190:S60–S68.
- Wang C, Wang XH, Nelson AL, Lee KK, Cui YG, Tong JS, Berman N, Lumbrelas L, Leung A, Hull L, Desai S, Swerdloff RS. Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. *J Clin Endocrinol Metab.* 2006;91:460–470.
- World Health Organization, *Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction.* 4th ed. Cambridge, United Kingdom: Cambridge University Press; 1999.

- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. *Fertil Steril*. 1996;65:821–829.
- World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. *Lancet*. 1990;336:955–959.
- Wu FC, Balasubramanian R, Mulders TM, Coelingh-Bennink HJ. Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism. *J Clin Endocrinol Metab*. 1999;84:112–122.
- Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A clinical trial of injectable testosterone undecanoate as a potential male contraceptive in normal Chinese men. *J Clin Endocrinol Metab*. 1999;84:3642–3647.
- Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men. *J Androl*. 1998;19:761–768.